Compounds > ciglitazone

ciglitazone and dactinomycin

ciglitazone has been researched along with dactinomycin in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Levine, L1
Coffey, MJ; Hayes, MM; King, SR; Lane, BR; Markovitz, DM1
Kim, HK; Kim, HS; Kim, HY; Kim, JR1
Cheon, H; Choi, SJ; Ji, JD; Kim, HJ; Lee, YH; Rho, YH; Sohn, J; Song, GG; Um, JW1

Other Studies

6 other study(ies) available for ciglitazone and dactinomycin

ArticleYear
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Stimulated release of arachidonic acid by agonists of the peroxisome proliferator-activated receptor and retinoic acid receptors.
    Prostaglandins, leukotrienes, and essential fatty acids, 2001, Volume: 65, Issue:4

    Topics: Alitretinoin; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Cell Line; Cycloheximide; Dactinomycin; Dose-Response Relationship, Drug; Drug Synergism; Indomethacin; Kinetics; Liver; Prostaglandin D2; Prostaglandins A; Pyrazoles; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Sulfonamides; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin

2001
Peroxisome proliferator-activated receptor gamma agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects.
    The Journal of biological chemistry, 2002, May-10, Volume: 277, Issue:19

    Topics: Cell Line; Cells, Cultured; Dactinomycin; Dose-Response Relationship, Drug; HeLa Cells; HIV-1; Humans; Hypoglycemic Agents; Macrophages; Plasmids; Promoter Regions, Genetic; Prostaglandins A; Protein Synthesis Inhibitors; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA Processing, Post-Transcriptional; RNA-Directed DNA Polymerase; RNA, Messenger; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; U937 Cells

2002
Upregulation of LPS-induced chemokine KC expression by 15-deoxy-delta12,14-prostaglandin J2 in mouse peritoneal macrophages.
    Immunology and cell biology, 2005, Volume: 83, Issue:3

    Topics: Animals; Blotting, Northern; Chemokine CXCL1; Chemokines, CXC; Cycloheximide; Dactinomycin; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Flavonoids; Gene Expression; Hypoglycemic Agents; Immunologic Factors; Intercellular Signaling Peptides and Proteins; Lipopolysaccharides; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; PPAR gamma; Prostaglandin D2; Pyrrolidines; RNA Stability; RNA, Messenger; Specific Pathogen-Free Organisms; Thiazolidinediones; Thiocarbamates; Time Factors; Up-Regulation

2005
15-Deoxy-delta12,14-PGJ2 inhibits IL-6-induced Stat3 phosphorylation in lymphocytes.
    Experimental & molecular medicine, 2005, Jun-30, Volume: 37, Issue:3

    Topics: Arthritis, Rheumatoid; Chromans; Cycloheximide; Dactinomycin; DNA-Binding Proteins; Gene Expression Regulation; Humans; Hypoglycemic Agents; Interleukin-6; Jurkat Cells; Lymphocytes; NF-kappa B; Phosphorylation; PPAR gamma; Prostaglandin D2; Protein Synthesis Inhibitors; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Thiazolidinediones; Trans-Activators; Troglitazone

2005